Skip to main content

Table 4 Cohen’s d effect size for significant efficacy parameters

From: Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study

Domain Parameter ITT population mITT population PP population Effect sizea
CSF QC activity 1.25*** 1.28*** 1.66*** ↓ large
EEG Relative theta power 0.29** 0.32*** 0.37** ↓ small–moderate
NTB
CSF
One Back Test 0.23* 0.23 0.20 ↓ small
Neurogranin 0.16 0.20* 0.12 ↓ small
YKL-40 0.16 0.16 0.20* ↓ small
  1. CSF cerebrospinal fluid, EEG electroencephalogram, ITT intent to treat, mITT modified ITT, NTB Neuropsychological Test Battery, PP per protocol, QC glutaminyl cyclase
  2. aArrow indicates direction of treatment effect (↓ decrease)
  3. 0.05 < p ≤ 0.10
  4. *0.01 < p ≤ 0.05
  5. **0.001 < p ≤ 0.01
  6. ***p ≤ 0.001
\